Northwest Biotherapeutics (NWBO) Enterprise Value (2010 - 2026)

Northwest Biotherapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 35.73% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$1.8 million (up 35.73% YoY), while the FY2025 annual figure was -$3.0 million, down 39.77% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.8 million, up from -$3.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$1.4 million in Q2 2023, with the low at -$9.4 million in Q3 2022.
• The 5-year median for Enterprise Value is -$3.0 million (2025), against an average of -$4.2 million.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 145.7% in 2022, then soared 70.52% in 2023.
• Northwest Biotherapeutics' Enterprise Value stood at -$7.0 million in 2022, then surged by 69.48% to -$2.1 million in 2023, then retreated by 2.3% to -$2.2 million in 2024, then sank by 39.77% to -$3.0 million in 2025, then surged by 41.25% to -$1.8 million in 2026.
• Business Quant data shows NWBO's Enterprise Value at -$1.8 million in Q1 2026, -$3.0 million in Q4 2025, and -$4.6 million in Q3 2025.